Prekyba Ionis Pharmaceuticals, Inc. - IONS CFD
Pridėti prie mėgstamų- Santrauka
- Istoriniai duomenys
- Įvykiai
- Pajamų ataskaita
- Balansas
- Pinigų srautai
- Nuosavybė
Skirtumas | 0.13 | ||||||||
Ilgos pozicijos nakties mokestis
Long position overnight fee
Eiti į platformą | -0.024874% | ||||||||
Trumpos pozicijos nakties mokestis
Short position overnight fee
Eiti į platformą | 0.002651% | ||||||||
Nakties mokesčio laikas | 21:00 (UTC) | ||||||||
Mažiausias parduodamas kiekis | 1 | ||||||||
Valiuta | USD | ||||||||
Marža | 20% | ||||||||
Akcijų birža | United States of America | ||||||||
Prekybos mokesčiai | 0% |
*Information provided by Capital.com
Ankstesnis uždarymas* | 35.33 |
Atviras* | 35.48 |
1 metų pokytis* | -2.23% |
Dienos intervalas* | 34.36 - 35.48 |
52 savaičių intervalas | 31.46-48.82 |
Vidutinė apimtis (10 dienų) | 1.12M |
Vidutinė apimtis (3 mėn.) | 19.93M |
Rinkos kapitalizacija | 4.90B |
P/E santykis | -100.00K |
Neišpirktos akcijos | 142.95M |
Pajamos | 587.37M |
EPS | -1.90 |
Dividendai (pajamingumas %) | N/A |
Beta | 0.54 |
Kito pelno data | May 2, 2023 |
Visus duomenis pateikė Refinitiv, išskyrus žvaigždute pažymėtus duomenis, kurie yra Capital.com pateikti *duomenys
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Uždarymas | Change | Change (%) | Atidarymas | High | Low |
---|---|---|---|---|---|---|
Mar 29, 2023 | 35.33 | 0.61 | 1.76% | 34.72 | 35.47 | 33.40 |
Mar 28, 2023 | 34.27 | 1.69 | 5.19% | 32.58 | 34.33 | 32.58 |
Mar 27, 2023 | 33.67 | -0.24 | -0.71% | 33.91 | 34.30 | 33.46 |
Mar 24, 2023 | 33.91 | 0.61 | 1.83% | 33.30 | 34.13 | 32.65 |
Mar 23, 2023 | 33.61 | -1.58 | -4.49% | 35.19 | 35.41 | 33.28 |
Mar 22, 2023 | 35.16 | 0.14 | 0.40% | 35.02 | 35.57 | 34.55 |
Mar 21, 2023 | 35.47 | 0.53 | 1.52% | 34.94 | 35.75 | 34.67 |
Mar 20, 2023 | 35.45 | -0.31 | -0.87% | 35.76 | 36.04 | 35.03 |
Mar 17, 2023 | 35.04 | 0.77 | 2.25% | 34.27 | 35.20 | 33.70 |
Mar 16, 2023 | 34.86 | 1.50 | 4.50% | 33.36 | 35.00 | 33.36 |
Mar 15, 2023 | 34.15 | 0.99 | 2.99% | 33.16 | 34.18 | 32.63 |
Mar 14, 2023 | 33.74 | 0.43 | 1.29% | 33.31 | 33.88 | 32.39 |
Mar 13, 2023 | 33.50 | 0.15 | 0.45% | 33.35 | 34.65 | 33.35 |
Mar 10, 2023 | 33.91 | 0.05 | 0.15% | 33.86 | 34.75 | 33.52 |
Mar 9, 2023 | 34.62 | -0.80 | -2.26% | 35.42 | 35.72 | 34.28 |
Mar 8, 2023 | 35.62 | 0.12 | 0.34% | 35.50 | 35.83 | 35.15 |
Mar 7, 2023 | 35.65 | -0.22 | -0.61% | 35.87 | 36.14 | 35.49 |
Mar 6, 2023 | 36.12 | -0.10 | -0.28% | 36.22 | 36.63 | 35.81 |
Mar 3, 2023 | 36.45 | 0.91 | 2.56% | 35.54 | 36.71 | 35.01 |
Mar 2, 2023 | 35.66 | 0.39 | 1.11% | 35.27 | 35.84 | 35.07 |
Ionis Pharmaceuticals, Inc. Events
Laikas (UTC) (UTC) | Šalis | Įvykis |
---|---|---|
No events scheduled |
- Metinis
- Kas ketvirtį
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Visos pajamos | 587.367 | 810.456 | 729.264 | 1122.6 | 599.674 |
Pajamos | 587.367 | 810.456 | 729.264 | 1122.6 | 599.674 |
Bendros pajamos, iš viso | 14.116 | 10.842 | 11.947 | 4.384 | 1.82 |
Pajamos | 573.251 | 799.614 | 717.317 | 1118.21 | 597.854 |
Pajamų sąnaudos, iš viso | 997.558 | 849.269 | 901.346 | 822.912 | 661.046 |
Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 150.295 | 170.947 | 332.222 | 286.644 | 244.622 |
Tyrimai ir plėtra | 833.147 | 634.953 | 526.877 | 465.688 | 414.604 |
Neįprastos išlaidos (pajamos) | 32.527 | 30.3 | 66.196 | 0 | |
Veiklos pajamos | -410.191 | -38.813 | -172.082 | 299.687 | -61.372 |
Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 9.876 | 10.798 | 37.592 | 39.765 | -14.602 |
Kita, pajamos | -7.274 | -1.133 | -0.062 | -0.686 | -0.182 |
Grynosios pajamos prieš mokesčius | -257.985 | -29.148 | -134.552 | 338.766 | -76.156 |
Grynosios pajamos po mokesčių | -269.722 | -28.597 | -479.743 | 287.259 | -117.115 |
Mažumos palūkanos | 0 | 0 | 35.48 | -9.116 | 58.756 |
Grynosios pajamos prieš papildomas. Prekės | -269.722 | -28.597 | -444.263 | 278.143 | -58.359 |
Grynosios pajamos | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | -269.722 | -28.597 | -444.263 | 278.143 | -58.359 |
Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Skiedimo koregavimas | 0 | ||||
Skiedžiamas grynasis pelnas | -269.722 | -28.597 | -444.263 | 278.143 | 273.741 |
Skiedžiamas svertinis vidutinis akcijų skaičius | 141.848 | 141.021 | 139.612 | 153.164 | 134.056 |
Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | -1.90149 | -0.20279 | -3.18213 | 1.81598 | -0.43533 |
Skiedžiamas normalizuotas pelnas, gautas iš pelno | -2.58703 | -0.05286 | -3.04106 | 2.18246 | -0.43533 |
Iš viso nepaprastųjų prekių | 332.1 | ||||
Gain (Loss) on Sale of Assets | 149.604 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Visos pajamos | 151.889 | 159.767 | 133.791 | 141.919 | 440.006 |
Pajamos | 151.889 | 159.767 | 133.791 | 141.919 | 440.006 |
Bendros pajamos, iš viso | 3.686 | 1.515 | 4.745 | 4.17 | 2.226 |
Pajamos | 148.203 | 158.252 | 129.046 | 137.749 | 437.78 |
Pajamų sąnaudos, iš viso | 359.908 | 218.921 | 219.305 | 199.423 | 219.401 |
Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 47.95 | 34.416 | 33.802 | 34.127 | 37.6 |
Tyrimai ir plėtra | 308.272 | 182.99 | 180.758 | 161.126 | 179.575 |
Veiklos pajamos | -208.019 | -59.154 | -85.514 | -57.504 | 220.605 |
Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 13.436 | 7.732 | -5.064 | -6.754 | 4.788 |
Kita, pajamos | 0.649 | 4.713 | -12.297 | 0.187 | -0.477 |
Grynosios pajamos prieš mokesčius | -44.33 | -46.709 | -102.875 | -64.071 | 224.916 |
Grynosios pajamos po mokesčių | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Mažumos palūkanos | 0 | 0 | |||
Grynosios pajamos prieš papildomas. Prekės | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Grynosios pajamos | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Skiedžiamas grynasis pelnas | -52.43 | -46.992 | -105.135 | -65.165 | 224.613 |
Skiedžiamas svertinis vidutinis akcijų skaičius | 142.046 | 141.95 | 141.794 | 141.599 | 141.21 |
Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | -0.36911 | -0.33105 | -0.74146 | -0.46021 | 1.59063 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Skiedžiamas normalizuotas pelnas, gautas iš pelno | -1.05369 | -0.33105 | -0.74146 | -0.46021 | 1.59063 |
Neįprastos išlaidos (pajamos) | 0 | ||||
Gain (Loss) on Sale of Assets | 149.604 |
- Metinis
- Kas ketvirtį
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Trumpalaikis turtas iš viso | 2345.05 | 2130.71 | 2720.6 | 2207.89 | 1168.73 |
Pinigai ir trumpalaikės investicijos | 2114.97 | 1892.38 | 2499.54 | 2084.07 | 1022.72 |
Pinigai ir ekvivalentai | 869.191 | 397.664 | 683.287 | 278.82 | 129.63 |
Trumpalaikės investicijos | 1245.78 | 1494.71 | 1816.26 | 1805.25 | 893.085 |
Gautinos sumos, iš viso, grynąja verte | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
Accounts Receivable - Trade, Net | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
Total Inventory | 24.806 | 21.965 | 18.18 | 8.582 | 9.982 |
Other Current Assets, Total | 143.374 | 140.163 | 139.839 | 102.473 | 73.082 |
Total Assets | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
Property/Plant/Equipment, Total - Net | 196.069 | 181.077 | 166.251 | 132.16 | 121.907 |
Property/Plant/Equipment, Total - Gross | 298.722 | 240.264 | 193.634 | 209.583 | |
Accumulated Depreciation, Total | -102.653 | -74.013 | -61.474 | -87.676 | |
Intangibles, Net | 29.005 | 27.937 | 25.674 | 24.032 | 22.004 |
Other Long Term Assets, Total | 41.567 | 50.034 | 320.59 | 303.706 | 10.129 |
Total Current Liabilities | 240.55 | 598.898 | 273.005 | 280.294 | 243.612 |
Accounts Payable | 11.904 | 17.199 | 16.067 | 28.66 | 24.886 |
Accrued Expenses | 129.97 | 155.889 | 106.152 | 77.629 | 91.769 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.926 | 316.11 | 13.749 | 1.621 | |
Other Current Liabilities, Total | 97.75 | 109.7 | 150.786 | 160.256 | 125.336 |
Total Liabilities | 1839.95 | 1646.47 | 1762.02 | 1619.7 | 1041.76 |
Total Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
Capital Lease Obligations | |||||
Other Liabilities, Total | 371.379 | 424.046 | 505.26 | 567.359 | 108.026 |
Total Equity | 771.737 | 743.282 | 1471.09 | 1048.08 | 281.013 |
Common Stock | 0.141 | 0.14 | 0.14 | 0.138 | 0.125 |
Additional Paid-In Capital | 1964.17 | 1895.52 | 2203.78 | 2047.25 | 1553.68 |
Retained Earnings (Accumulated Deficit) | -1159.9 | -1131.31 | -707.534 | -967.293 | -1241.03 |
Other Equity, Total | -32.668 | -21.071 | -25.29 | -32.016 | -31.759 |
Total Liabilities & Shareholders’ Equity | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
Total Common Shares Outstanding | 141.21 | 140.366 | 140.34 | 137.929 | 124.976 |
Minority Interest | 213.453 | 139.081 | 84.267 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Trumpalaikis turtas iš viso | 2253.12 | 2345.05 | 2155.74 | 2238.42 | 1989.42 |
Pinigai ir trumpalaikės investicijos | 2052.39 | 2114.97 | 1987.1 | 2059.27 | 1819.99 |
Pinigai ir ekvivalentai | 542.513 | 869.191 | 632.953 | 565.119 | 414.155 |
Trumpalaikės investicijos | 1509.88 | 1245.78 | 1354.15 | 1494.15 | 1405.84 |
Gautinos sumos, iš viso, grynąja verte | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
Accounts Receivable - Trade, Net | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
Total Inventory | 24.032 | 24.806 | 22.93 | 24.099 | 22.199 |
Other Current Assets, Total | 150.577 | 143.374 | 136.643 | 131.045 | 123.827 |
Total Assets | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
Property/Plant/Equipment, Total - Net | 177.724 | 196.069 | 180.144 | 179.316 | 180.413 |
Intangibles, Net | 29.295 | 29.005 | 30.038 | 29.373 | 28.795 |
Other Long Term Assets, Total | 58.949 | 41.567 | 48.971 | 49.962 | 49.925 |
Total Current Liabilities | 228.45 | 240.55 | 279.778 | 293.825 | 295.105 |
Accounts Payable | 16.125 | 11.904 | 8.357 | 14.658 | 9.506 |
Accrued Expenses | 115.781 | 129.97 | 108.001 | 105.372 | 108.029 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.206 | 0.926 | 65.045 | 69.848 | 69.504 |
Other Current Liabilities, Total | 92.338 | 97.75 | 98.375 | 103.947 | 108.066 |
Total Liabilities | 1809.52 | 1839.95 | 1884.36 | 1914.4 | 1567.99 |
Total Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
Other Liabilities, Total | 333.138 | 371.379 | 362.887 | 379.874 | 401.966 |
Total Equity | 709.574 | 771.737 | 530.536 | 582.674 | 680.564 |
Common Stock | 0.142 | 0.141 | 0.141 | 0.141 | 0.141 |
Additional Paid-In Capital | 1983.08 | 1964.17 | 1942.35 | 1910.38 | 1925.8 |
Retained Earnings (Accumulated Deficit) | -1225.07 | -1159.9 | -1384.52 | -1302.05 | -1221.18 |
Other Equity, Total | -48.578 | -32.668 | -27.437 | -25.796 | -24.203 |
Total Liabilities & Shareholders’ Equity | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
Total Common Shares Outstanding | 141.753 | 141.21 | 141.184 | 141.022 | 140.924 |
- Metinis
- Kas ketvirtį
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Grynosios pajamos / pradinė eilutė | -28.597 | -479.743 | 287.259 | 214.985 | -10.783 |
Pagrindinės veiklos pinigai | 30.799 | 35.892 | 345.627 | 602.906 | 174.149 |
Pagrindinės veiklos pinigai | 15.487 | 13.365 | 12.54 | 10.706 | 6.708 |
Amortization | 2.352 | 2.064 | 1.912 | 1.822 | 1.641 |
Deferred Taxes | 0 | 341.729 | 0.911 | -290.516 | 0 |
Nepiniginės prekės | 155.375 | 232.032 | 211.806 | 166.484 | 139.539 |
Sumokėtos palūkanos grynaisiais pinigais | 4.778 | 6.247 | 9.87 | 9.592 | 8.035 |
Apyvartinio kapitalo pokyčiai | -113.818 | -73.555 | -168.801 | 499.425 | 37.044 |
Investicinės veiklos pinigai | 194.906 | 274.477 | -41.274 | -929.563 | -358.291 |
Kapitalo išlaidos | -11.955 | -35.12 | -30.905 | -13.608 | -34.764 |
Kiti investiciniai pinigų srautų iš prekių, iš viso | 206.861 | 309.597 | -10.369 | -915.955 | -323.527 |
Finansinės veiklos pinigai | 245.933 | -596.609 | 100.021 | 475.865 | 229.087 |
Finansavimo pinigų srautų prekės | -168.954 | -558.097 | -138.354 | 0 | 47.963 |
Akcijų išleidimas (išpirkimas), grynasis | 101.317 | -38.512 | 141.375 | 475.865 | 205.106 |
Skolos išleidimas (padengimas), grynasis | 313.57 | 0 | 97 | 0 | -23.982 |
Grynasis pinigų pokytis | 471.527 | -285.623 | 404.467 | 149.19 | 44.945 |
Cash Taxes Paid | 0.038 | 25.855 | 9.041 | 0 | |
Užsienio valiutos keitimo įtaka | -0.111 | 0.617 | 0.093 | -0.018 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -65.165 | -28.597 | -253.21 | -170.744 | -89.869 |
Cash From Operating Activities | -31.65 | 30.799 | -172.888 | -117.314 | -54.662 |
Cash From Operating Activities | 3.701 | 15.487 | 11.665 | 7.951 | 3.917 |
Amortization | 0.592 | 2.352 | 1.74 | 1.137 | 0.544 |
Deferred Taxes | 0 | 0 | 0 | 0 | |
Non-Cash Items | 32.983 | 155.375 | 125.535 | 88.261 | 43.346 |
Cash Taxes Paid | 0.002 | 0.038 | 0.003 | 0.002 | |
Cash Interest Paid | 0.594 | 4.778 | 3.527 | 2.866 | 0.594 |
Changes in Working Capital | -3.761 | -113.818 | -58.618 | -43.919 | -12.6 |
Cash From Investing Activities | -287.549 | 194.906 | 99.797 | -22.174 | 78.856 |
Capital Expenditures | -2.705 | -11.955 | -9.453 | -6.13 | -1.772 |
Other Investing Cash Flow Items, Total | -284.844 | 206.861 | 109.25 | -16.044 | 80.628 |
Cash From Financing Activities | -7.325 | 245.933 | 308.423 | 306.965 | -7.577 |
Financing Cash Flow Items | -9.173 | -168.954 | -168.43 | -167.966 | -15.337 |
Issuance (Retirement) of Stock, Net | 1.848 | 101.317 | 101.316 | 99.394 | 7.76 |
Foreign Exchange Effects | -0.154 | -0.111 | -0.043 | -0.022 | -0.126 |
Net Change in Cash | -326.678 | 471.527 | 235.289 | 167.455 | 16.491 |
Issuance (Retirement) of Debt, Net | 313.57 | 375.537 | 375.537 |
Investuotojo pavadinimas | Investuotojo tipas | Apyvartoje esantis procentas | Turimos akcijos | Turimų akcijų pokytis | Turėjimo data | Apyvartos vertinimas |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 14.9052 | 21307519 | 16360 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.4574 | 13519789 | 736550 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 8.1692 | 11678259 | 521564 | 2022-12-31 | MED |
Bellevue Asset Management AG | Investment Advisor | 6.8161 | 9743900 | 280500 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.986 | 7127720 | 135266 | 2022-12-31 | LOW |
ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 3.7954 | 5425642 | -348250 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.9511 | 4218729 | 457774 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.9049 | 4152607 | -508999 | 2022-12-31 | LOW |
Tweedy, Browne Company LLC | Investment Advisor | 2.4771 | 3541136 | 818148 | 2022-12-31 | LOW |
ARK Investment Management LLC | Investment Advisor | 1.8702 | 2673538 | -1039569 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.408 | 2012723 | 111580 | 2022-12-31 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.3946 | 1993600 | 1224700 | 2022-12-31 | LOW |
Camber Capital Management LP | Hedge Fund | 1.3466 | 1925000 | 0 | 2022-12-31 | MED |
First Trust Advisors L.P. | Investment Advisor | 1.2458 | 1780933 | -296327 | 2022-12-31 | LOW |
Macquarie Investment Management | Investment Advisor | 1.0435 | 1491687 | 657646 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.907 | 1296647 | 465428 | 2022-12-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.8788 | 1256268 | 53922 | 2022-12-31 | LOW |
Deep Track Capital LP | Hedge Fund | 0.8435 | 1205773 | 1205773 | 2022-12-31 | MED |
Renaissance Technologies LLC | Hedge Fund | 0.8246 | 1178814 | 311100 | 2022-12-31 | HIGH |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7966 | 1138714 | 15634 | 2022-12-31 | LOW |
Kodėl Capital.com? Mūsų skaičiai kalba už save.
Capital.com Group500K+
Prekeiviai
92K+
Aktyvūs klientai kas mėnesį
$53M+
Mėnesio investicijų apimtis
$30M+
Atsiimama kas mėnesį
Prekybos skaičiuoklė
Apskaičiuokite savo hipotetinį pelną ir pelną, jei CFD sandorį atidarėte tam tikrą dieną (pasirinkite datą) ir uždarėte kitą dieną (pasirinkite datą).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ionis Pharmaceuticals Company profile
Apie Ionis Pharmaceuticals, Inc.
"Ionis Pharmaceuticals, Inc." užsiima į ribonukleorūgštis (RNR) orientuotų gydymo metodų atradimu ir kūrimu. Bendrovė daugiausia dėmesio skiria širdies ir kraujagyslių bei neurologijos sritims. Jos produktai yra SPINRAZA, TEGSEDI ir WAYLIVRA. SPINRAZA yra skirtas įvairaus amžiaus pacientams, sergantiems spinaline raumenų atrofija (SMA) - progresuojančia, silpnėjančia ir dažnai mirtina genetine liga, gydyti. TEGSEDI skirtas pacientams, sergantiems polineuropatija, kurią sukelia paveldima transtiretino (TTR), amiloidozė (hATTR) - alinanti, progresuojanti ir mirtina liga, gydyti. WAYLIVRA yra antisensorinis vaistinis preparatas, skirtas suaugusiems pacientams kaip priedas prie dietos. Bendrovė vykdo daugiau nei šešių vaistų III fazės tyrimus pagal aštuonias indikacijas: "Eplontersen" (TTR), "Olezarsen" (ApoC-III), "Donidalorsen" (PKK), "ION363" (FUS), "Pelacarsen" (Apo(a)) ir "Tofersen" (SOD1). Kuriami širdies ir kraujagyslių vaistai: "Eplontersen", "Olezarsen", "Pelacarsen", ION449 (PCSK9), "Fesomersen" ir "IONIS-AGT-LRx".
Industry: | Biotechnology & Medical Research (NEC) |
2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US
Pajamų ataskaita
- Annual
- Quarterly
Žmonės taip pat žiūri
Vis dar ieškote brokerio kuriuo galėtumėte pasitikėti?
Prisijunkite prie 500 000+ prekeivių visame pasaulyje, kurie pasirinko prekybą su Capital.com